Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injectio

10월 21일 11:48

Vifor Pharma announces outcome of AFFIRM-AHF topline data

Regulatory News: Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject® (intravenous ferric carboxymaltose) on heart failure hospitalizations and ca

9월 25일 17:43

Vifor Pharma Group Announces Successful Sale of OM Pharma

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:

9월 18일 16:02

Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee

Regulatory News: Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020. Gregory

9월 1일 16:37

Vifor Pharma Group Reports Continued Growth in H1 2020

Regulatory News: Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect C

8월 6일 15:02

VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six (46) patient phase-II dose-ranging trial in

5월 18일 17:36

92nd Vifor Pharma Group Annual General Meeting

Regulatory News: At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the current situation a

5월 15일 16:31

Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients

Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes progr

5월 6일 10:36

Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance

Regulatory News: Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The c

3월 12일 15:35

Pioneering Project for Pharmaceutics - Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

Nanopharmaceutics promises ground-breaking innovation in the development of medicines: · The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the U

2019년 5월 27일 10:53